ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
21.66
+0.03 (0.14%)
May 29, 2026, 4:00 PM EDT - Market closed
ACADIA Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,095 | 1,072 | 957.8 | 726.44 | 517.24 | 484.15 | |
Revenue Growth (YoY) | 9.93% | 11.87% | 31.85% | 40.45% | 6.83% | 9.60% |
Cost of Revenue | 93.4 | 89 | 81.84 | 41.64 | 10.17 | 19.14 |
Gross Profit | 1,002 | 982.51 | 875.96 | 684.8 | 507.07 | 465 |
Selling, General & Admin | 593.54 | 548.89 | 488.43 | 406.56 | 369.09 | 396.03 |
Research & Development | 327.41 | 328.8 | 303.25 | 351.62 | 361.58 | 239.42 |
Other Operating Expenses | - | - | -146.52 | - | - | - |
Total Operating Expenses | 920.95 | 877.7 | 645.16 | 758.18 | 730.67 | 635.44 |
Operating Income | 80.91 | 104.81 | 230.79 | -73.38 | -223.6 | -170.44 |
Interest Income | 31.88 | 31.72 | 25.46 | 17.23 | 6.61 | 0.59 |
Other Non-Operating Income (Expense) | 2.33 | 2.37 | 1.82 | 5.11 | 3.54 | 2.33 |
Total Non-Operating Income (Expense) | 34.2 | 34.09 | 27.28 | 22.34 | 10.15 | 2.92 |
Pretax Income | 115.11 | 138.9 | 258.08 | -51.04 | -213.44 | -167.52 |
Provision for Income Taxes | -260.54 | -252.1 | 31.62 | 10.25 | 2.53 | 0.35 |
Net Income | 375.65 | 391 | 226.45 | -61.29 | -215.98 | -167.87 |
Net Income to Common | 375.65 | 391 | 226.45 | -61.29 | -215.98 | -167.87 |
Net Income Growth | 64.12% | 72.66% | - | - | - | - |
Shares Outstanding (Basic) | 169 | 168 | 166 | 164 | 162 | 160 |
Shares Outstanding (Diluted) | 171 | 170 | 166 | 164 | 162 | 160 |
Shares Change (YoY) | 2.50% | 2.14% | 1.55% | 1.32% | 0.74% | 2.01% |
EPS (Basic) | 2.23 | 2.32 | 1.37 | -0.37 | -1.34 | -1.05 |
EPS (Diluted) | 2.20 | 2.30 | 1.36 | -0.37 | -1.34 | -1.05 |
EPS Growth | 60.58% | 69.12% | - | - | - | - |
Shares Outstanding | 171.09 | 170.31 | 166.71 | 164.65 | 162.07 | 161.01 |
Free Cash Flow | 113.59 | 105.15 | 157.2 | 16.65 | -114.04 | -126.78 |
Free Cash Flow Growth | 8.03% | -33.11% | 844.01% | - | - | - |
Free Cash Flow Per Share | 0.66 | 0.62 | 0.94 | 0.10 | -0.71 | -0.79 |
Gross Margin | 91.47% | 91.69% | 91.46% | 94.27% | 98.03% | 96.05% |
Operating Margin | 7.39% | 9.78% | 24.10% | -10.10% | -43.23% | -35.20% |
Profit Margin | 34.30% | 36.49% | 23.64% | -8.44% | -41.76% | -34.67% |
FCF Margin | 10.37% | 9.81% | 16.41% | 2.29% | -22.05% | -26.19% |
EBITDA | 92.71 | 116.57 | 246.68 | -67.83 | -223.6 | -167.1 |
EBITDA Margin | 8.46% | 10.88% | 25.75% | -9.34% | -43.23% | -34.51% |
EBIT | 80.91 | 104.81 | 230.79 | -73.38 | -223.6 | -170.44 |
EBIT Margin | 7.39% | 9.78% | 24.10% | -10.10% | -43.23% | -35.20% |
Effective Tax Rate | -226.35% | -181.49% | 12.25% | -20.08% | -1.19% | -0.21% |